About Pearl Huang

Dr. Huang brings decades of experience spanning the biotech and pharmaceutical industries, with oversight across early drug discovery and development, translational research and alliance management. Prior to Dunad, she was Chief Executive Officer and President of Cygnal Therapeutics, founded by Flagship Pioneering, where she was also a venture partner. Earlier, she held leadership roles at Roche as Senior Vice President of Therapeutic Modalities, at GSK as Vice President, Global Head of Discovery Partnerships with Academia (DPAc) and at Merck as Vice President, Oncology Franchise Integrator. She was also a Founder and Acting Chief Scientific Officer of Beigene. Dr. Huang serves on the board of directors for KSQ Therapeutics, Waters Corporation and BB Biotech, and is a member of the MIT Corporation. She received her S.B. in life sciences from Massachusetts Institute of Technology and her Ph.D. in molecular biology from Princeton University. She will be based in Cambridge, Massachusetts.